SI1648933T1 - Long lasting insulin derivatives and methods thereof - Google Patents

Long lasting insulin derivatives and methods thereof

Info

Publication number
SI1648933T1
SI1648933T1 SI200431199T SI200431199T SI1648933T1 SI 1648933 T1 SI1648933 T1 SI 1648933T1 SI 200431199 T SI200431199 T SI 200431199T SI 200431199 T SI200431199 T SI 200431199T SI 1648933 T1 SI1648933 T1 SI 1648933T1
Authority
SI
Slovenia
Prior art keywords
methods
long lasting
insulin derivatives
insulin molecule
lasting insulin
Prior art date
Application number
SI200431199T
Other languages
Slovenian (sl)
Inventor
Dominique P Bridon
Jean-Paul Castaigne
Xicai Huang
Roger Leger
Martin Robitaille
Original Assignee
Conjuchem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34118817&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1648933(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conjuchem Biotechnologies Inc filed Critical Conjuchem Biotechnologies Inc
Publication of SI1648933T1 publication Critical patent/SI1648933T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Abstract

The present invention relates to an insulin derivative comprising an insulin molecule and a reactive group for covalently bonding a blood component, wherein preferably the insulin molecule is human natural insulin molecule and the reactive group is coupled to an amino acid of the insulin molecule at a position selected from the positions Gly A1, Phe B1 and Lys B29.
SI200431199T 2003-07-25 2004-07-26 Long lasting insulin derivatives and methods thereof SI1648933T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US49011003P 2003-07-25 2003-07-25
US55658504P 2004-03-25 2004-03-25
PCT/CA2004/001409 WO2005012346A1 (en) 2003-07-25 2004-07-26 Long lasting insulin derivatives and methods thereof
EP04801809A EP1648933B1 (en) 2003-07-25 2004-07-26 Long lasting insulin derivatives and methods thereof

Publications (1)

Publication Number Publication Date
SI1648933T1 true SI1648933T1 (en) 2010-01-29

Family

ID=34118817

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200431199T SI1648933T1 (en) 2003-07-25 2004-07-26 Long lasting insulin derivatives and methods thereof

Country Status (16)

Country Link
US (1) US20060241019A1 (en)
EP (2) EP1648933B1 (en)
JP (2) JP2007520441A (en)
AT (1) ATE433994T1 (en)
AU (2) AU2004261319B2 (en)
BR (1) BRPI0412252A (en)
CA (1) CA2526957C (en)
DE (1) DE602004021603D1 (en)
DK (1) DK1648933T3 (en)
EA (1) EA008433B1 (en)
ES (1) ES2328579T3 (en)
HK (1) HK1091843A1 (en)
NO (1) NO20060888L (en)
PL (1) PL1648933T3 (en)
SI (1) SI1648933T1 (en)
WO (1) WO2005012346A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6329336B1 (en) * 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
EA006160B1 (en) 2001-02-16 2005-10-27 Конджачем, Инк. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
TWI376234B (en) 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
KR101441444B1 (en) * 2006-05-09 2014-09-18 노보 노르디스크 에이/에스 Insulin derivative
KR101699370B1 (en) 2006-09-22 2017-02-14 노보 노르디스크 에이/에스 Protease resistant insulin analogues
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
CN101674812B (en) 2007-04-30 2013-12-11 诺沃-诺迪斯克有限公司 Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
EP2254905B1 (en) 2008-03-14 2016-12-14 Novo Nordisk A/S Protease-stabilized insulin analogues
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
ES2563553T3 (en) * 2008-04-01 2016-03-15 Novo Nordisk A/S Insulin-albumin conjugates
CA2750252A1 (en) * 2009-01-28 2010-08-05 Smartcells, Inc. Synthetic conjugates and uses thereof
WO2013153000A2 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
MX349035B (en) 2012-05-17 2017-07-07 Extend Biosciences Inc Carriers for improved drug delivery.
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
MA46146A1 (en) * 2014-01-20 2020-12-31 Hanmi Pharm Ind Co Ltd Long-acting insulin and associated use
AR100639A1 (en) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd COMPOSITION TO TREAT DIABETES THAT INCLUDES CONJUGATES OF PROLONGED INSULIN ANALOGS AND CONJUGATES OF PROLONGED INSULINOTROPIC PEPTIDES
AR100695A1 (en) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd COMPOSITION FOR THE TREATMENT OF MELLITUS DIABETES THAT INCLUDES INSULIN AND A DUAL AGONIST GLP-1 / GLUCAGÓN
KR20160001391A (en) * 2014-06-27 2016-01-06 한미약품 주식회사 Novel long acting insulin analog and use thereof
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
SG11201708356PA (en) 2015-05-07 2017-11-29 Codexis Inc Penicillin-g acylases
UY36870A (en) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd NEW INSULIN ANALOGS
JP7158378B2 (en) 2016-09-23 2022-10-21 ハンミ ファーマシューティカル カンパニー リミテッド Insulin analogue with reduced binding force with insulin receptor and use thereof
HUE055231T2 (en) 2016-12-16 2021-11-29 Novo Nordisk As Insulin containing pharmaceutical compositions
US11752216B2 (en) 2017-03-23 2023-09-12 Hanmi Pharm. Co., Ltd. Insulin analog complex with reduced affinity for insulin receptor and use thereof
CN113855678A (en) * 2021-09-08 2021-12-31 武汉生命奥义生物科技有限公司 Composition for adjuvant treatment of type II diabetes

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3509120A (en) * 1966-12-28 1970-04-28 Squibb & Sons Inc N-terminal mono- and diaminoacyl-insulin
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
JPS5272284A (en) * 1975-12-12 1977-06-16 Dainippon Pharmaceutical Co Enzymeeimmunoassay reagent
CA1196863A (en) * 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5422339A (en) * 1991-03-19 1995-06-06 Joslin Diabetes Center, Inc. Peptides having insulin autoantibody but not insulin receptor binding capacity
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
DK72793D0 (en) * 1993-06-21 1993-06-21 Novo Nordisk As NEW PRODUCT
US6342225B1 (en) * 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
DE122010000020I1 (en) * 1996-04-25 2010-07-08 Prosidion Ltd Method for lowering the blood glucose level in mammals
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
DE19726167B4 (en) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, process for its preparation and pharmaceutical preparation containing it
EP1039920A4 (en) * 1997-10-24 2003-05-28 Lilly Co Eli Fatty acid-acylated insulin analogs
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
EP1052994A2 (en) * 1998-02-02 2000-11-22 Trustees Of Tufts College Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
EP2332522A3 (en) * 1998-03-19 2011-12-07 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
JP2002518408A (en) * 1998-06-12 2002-06-25 キングス・カレツジ・ロンドン Insulin analogues
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
WO2000022112A1 (en) * 1998-10-13 2000-04-20 The University Of Georgia Research Foundation, Inc. Stabilized bioactive peptides and methods of identification, synthesis and use
CA2623458A1 (en) * 1999-05-17 2000-11-23 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6329336B1 (en) * 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
CA2415425A1 (en) * 2000-07-10 2002-01-17 Btg International Limited Insulin derivatives and synthesis thereof
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US20040143015A1 (en) * 2001-03-12 2004-07-22 Villhauer Edwin Bernard Combination of organic compounds
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
AU2003218635A1 (en) * 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
AU2003236521A1 (en) * 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
US20050065066A1 (en) * 2002-12-20 2005-03-24 Kaarsholm Niels Christian Stabilised insulin compositions
GB0309154D0 (en) * 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
US9040664B2 (en) * 2003-04-11 2015-05-26 Antriabio, Inc. Materials and methods for preparing protein-polymer conjugates
JO2625B1 (en) * 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
BRPI0413276B8 (en) * 2003-08-05 2021-05-25 Novo Nordisk As insulin derivative, zinc complex thereof, and pharmaceutical composition
CA2580313C (en) * 2004-07-19 2016-03-15 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
MX2008013165A (en) * 2006-04-12 2009-01-29 Biodel Inc Rapid acting and long acting insulin combination formulations.

Also Published As

Publication number Publication date
EP1648933B1 (en) 2009-06-17
WO2005012346A1 (en) 2005-02-10
ES2328579T3 (en) 2009-11-16
ATE433994T1 (en) 2009-07-15
EP1648933A4 (en) 2007-02-28
DK1648933T3 (en) 2009-09-07
CA2526957A1 (en) 2005-02-10
CA2526957C (en) 2011-07-12
HK1091843A1 (en) 2007-01-26
BRPI0412252A (en) 2006-09-19
US20060241019A1 (en) 2006-10-26
AU2011201278A1 (en) 2011-04-07
EA008433B1 (en) 2007-06-29
EP2085406A1 (en) 2009-08-05
JP2007520441A (en) 2007-07-26
EA200600305A1 (en) 2006-06-30
JP2012062311A (en) 2012-03-29
EP1648933A1 (en) 2006-04-26
PL1648933T3 (en) 2010-01-29
DE602004021603D1 (en) 2009-07-30
NO20060888L (en) 2006-04-25
AU2004261319B2 (en) 2010-12-23
AU2004261319A1 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
HK1091843A1 (en) Long lasting insulin derivatives and methods thereof
WO2005116068A8 (en) Peptides or peptidic conjugate derivatives of msh and the use thereof for cosmetically fighting against canities
WO2006050930A3 (en) Conjugates with enhanced cell uptake activity
EP2107069A3 (en) Novel insulin derivatives
EP1196444B8 (en) Exendin-4 conjugates and their medical use
WO2002055063A3 (en) Fumaric acid amides
RU2009129961A (en) GLUCAGON ANALOGUES HAVING AN INCREASED SOLUBILITY IN BUFFERS WITH PHYSIOLOGICAL VALUE OF pH
WO2007062610A3 (en) Four branched dendrimer-peg for conjugation to proteins and peptides
PL393178A1 (en) Heterogeneous fusion protein, pharmaceutical composition for the treatment of diabetic patients with insulin-independent diabetes and pharmaceutical composition for the treatment of obese patients
WO2008047241A3 (en) Modified corticotropin releasing factor peptides and uses thereof
TW200631592A (en) Soluble, stable insulin-containing formulations
WO2003028527A8 (en) Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof
WO2005115174A3 (en) Alpha-msh-antagonist didpeptide conjugates
WO2004027064A3 (en) Ghrh analogues
EP2275439A3 (en) Novel insulin derivatives
CY1111431T1 (en) METHODS OF PRACTICAL PLUMBING GROWTH FACTORS OF TYPE 1, METHOD OF PREPARATION AND THEIR APPLICATIONS
WO2007135117A3 (en) Soluble, stable insulin-containing formulations
WO2007050121A3 (en) Site specific pegylated hemoglobin, method of preparing same, and uses thereof
WO2004018502A8 (en) Compounds binding to p-selectin
EP1997826A3 (en) Synthetic ligands for immunoglobulins and pharmaceutical compositions containing them
WO2000070665A3 (en) Long lasting anti-angiogenic peptides
CA2498062A1 (en) Conjugates of insulin-like growth factor binding protein-4 and poly(ethylene glycol)
DE60234108D1 (en) Gen
WO2008070049A8 (en) Peptide and treatment for hiv-1 infection
HK1126790A1 (en) Biologically active peptide vapeehptllteaplnpk derivatives